search
Back to results

Efficacy and Tolerability of Baclofen for Alcohol Dependence

Primary Purpose

Alcohol Dependence

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
baclofen
placebo
BRENDA counseling
Sponsored by
University of North Carolina, Chapel Hill
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alcohol Dependence focused on measuring alcohol dependence, baclofen, pharmacotherapy, women

Eligibility Criteria

21 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  1. Men and women between the ages of 18 and 60 meeting DSM-IV criteria for current alcohol dependence.
  2. Must have had at least 2 heavy drinking days (men > 5 drinks/days; women > 4 drinks/day) per week, on average and an average overall consumption of 21 drinks/week or more for men and 14 drinks/week or more for women during the 4 weeks prior to screening.
  3. Able to understand and sign written informed consent.
  4. Must be willing to refrain from drinking for three days prior to randomization day.
  5. Express a desire to achieve abstinence or to greatly reduce alcohol consumption.
  6. Must have a stable residence and be able to identify an individual who could locate subject if needed.

Exclusion Criteria

  1. Clinically significant medical disease that might interfere with the evaluation of the study medication or present a safety concern (e.g., cirrhosis, kidney impairment, unstable hypertension, hypotension, diabetes mellitus, seizure disorder).
  2. Clinically significant psychiatric illness including any psychotic disorder, bipolar disorder, or severe depression; suicidal ideation; substance use disorder other than alcohol or nicotine dependence or cannabis abuse.
  3. History of complicated alcohol withdrawal, i.e. withdrawal seizure or delirium tremens.
  4. Concurrent use of any psychotropic medication including antidepressants, mood stabilizers, antipsychotics, anxiolytics, stimulants, or hypnotics. However, subjects who have been on stable doses of the antidepressants fluoxetine, sertraline, paroxetine, citalopram, ecitalapram, trazodone or venlafaxine for two months will be eligible. Subjects who have been taking benzodiazepines for alcohol detoxification will be required to have a washout period of at least five half-lives (approximately 5 days) from those medications before being randomized.
  5. Concurrent use of anticonvulsants, insulin, or oral hypoglycemics.
  6. AST, or ALT > 3 times Upper Limit of Normal (ULN), or bilirubin > ULN, or creatinine > ULN.
  7. Positive urine toxicology screen with the exception of cannabis. Individuals with positive cannabis screens will be excluded only if they have a history of cannabis dependence.
  8. Pregnant women and women of childbearing potential who do not practice a medically acceptable form of birth control (oral or depot contraceptive, or barrier methods such as diaphragm or condom with spermicidal).
  9. Women who are breastfeeding.
  10. Individuals requiring inpatient treatment or more intense outpatient treatment for their alcohol dependence.
  11. Participation in any clinical trial within the last 60 days.
  12. Court-mandated participation in alcohol treatment or pending incarceration.

Sites / Locations

  • University of North Carolina at Chapel Hill School of Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

1

2

Arm Description

Baclofen

Placebo

Outcomes

Primary Outcome Measures

% heavy drinking days

Secondary Outcome Measures

% relapse
% abstinent days
depression symptoms
anxiety symptoms

Full Information

First Posted
February 7, 2008
Last Updated
September 13, 2012
Sponsor
University of North Carolina, Chapel Hill
search

1. Study Identification

Unique Protocol Identification Number
NCT00877734
Brief Title
Efficacy and Tolerability of Baclofen for Alcohol Dependence
Official Title
Phase IIIa Trial of Baclofen for Alcohol Dependence
Study Type
Interventional

2. Study Status

Record Verification Date
April 2011
Overall Recruitment Status
Completed
Study Start Date
April 2005 (undefined)
Primary Completion Date
May 2007 (Actual)
Study Completion Date
June 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of North Carolina, Chapel Hill

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a study of the efficacy and safety of baclofen for alcohol dependence. 80 outpatient subjects with DSM-IV alcohol dependence will be randomized to 10 mg three times a day (tid) baclofen or tid placebo. An effort will be made to recruit 40 men and 40 women. Subjects will receive BRENDA counseling over the 12 weeks of the trial. The Timeline Followback (TLFB) method will be used to assess drinking patterns. The primary outcome is % heavy drinking during the trial.
Detailed Description
The study will explore the efficacy and tolerability of a 12-week regimen of 10 mg t.i.d. baclofen vs. placebo in conjunction with behavioral therapy for reducing heavy drinking in 80 alcohol dependent individuals. Prior studies (Addolorato et al. 2000, 2002; Flannery et al., 2004) have found that baclofen reduces self-reported anxiety and craving; therefore, the proposed study also will assess baclofen's ability to reduce symptoms of these affective states. Furthermore, in our pilot study (Flannery et al, 2004), women appeared to respond more consistently than men, and therefore the study will also be balanced by gender.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Dependence
Keywords
alcohol dependence, baclofen, pharmacotherapy, women

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Baclofen
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Drug
Intervention Name(s)
baclofen
Other Intervention Name(s)
Lioresal
Intervention Description
10 mg Baclofen administered tid for 11 weeks
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
Placebo administered tid for 11 weeks
Intervention Type
Behavioral
Intervention Name(s)
BRENDA counseling
Primary Outcome Measure Information:
Title
% heavy drinking days
Time Frame
2 years
Secondary Outcome Measure Information:
Title
% relapse
Time Frame
2 years
Title
% abstinent days
Time Frame
2 years
Title
depression symptoms
Time Frame
2 years
Title
anxiety symptoms
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Men and women between the ages of 18 and 60 meeting DSM-IV criteria for current alcohol dependence. Must have had at least 2 heavy drinking days (men > 5 drinks/days; women > 4 drinks/day) per week, on average and an average overall consumption of 21 drinks/week or more for men and 14 drinks/week or more for women during the 4 weeks prior to screening. Able to understand and sign written informed consent. Must be willing to refrain from drinking for three days prior to randomization day. Express a desire to achieve abstinence or to greatly reduce alcohol consumption. Must have a stable residence and be able to identify an individual who could locate subject if needed. Exclusion Criteria Clinically significant medical disease that might interfere with the evaluation of the study medication or present a safety concern (e.g., cirrhosis, kidney impairment, unstable hypertension, hypotension, diabetes mellitus, seizure disorder). Clinically significant psychiatric illness including any psychotic disorder, bipolar disorder, or severe depression; suicidal ideation; substance use disorder other than alcohol or nicotine dependence or cannabis abuse. History of complicated alcohol withdrawal, i.e. withdrawal seizure or delirium tremens. Concurrent use of any psychotropic medication including antidepressants, mood stabilizers, antipsychotics, anxiolytics, stimulants, or hypnotics. However, subjects who have been on stable doses of the antidepressants fluoxetine, sertraline, paroxetine, citalopram, ecitalapram, trazodone or venlafaxine for two months will be eligible. Subjects who have been taking benzodiazepines for alcohol detoxification will be required to have a washout period of at least five half-lives (approximately 5 days) from those medications before being randomized. Concurrent use of anticonvulsants, insulin, or oral hypoglycemics. AST, or ALT > 3 times Upper Limit of Normal (ULN), or bilirubin > ULN, or creatinine > ULN. Positive urine toxicology screen with the exception of cannabis. Individuals with positive cannabis screens will be excluded only if they have a history of cannabis dependence. Pregnant women and women of childbearing potential who do not practice a medically acceptable form of birth control (oral or depot contraceptive, or barrier methods such as diaphragm or condom with spermicidal). Women who are breastfeeding. Individuals requiring inpatient treatment or more intense outpatient treatment for their alcohol dependence. Participation in any clinical trial within the last 60 days. Court-mandated participation in alcohol treatment or pending incarceration.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James C Garbutt, MD
Organizational Affiliation
UNC Department of Psychiatry
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of North Carolina at Chapel Hill School of Medicine
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599-7160
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Tolerability of Baclofen for Alcohol Dependence

We'll reach out to this number within 24 hrs